🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer

RecruitingEARLY Phase 1Ages 18 Years - 75 YearsAllCancer Institute and Hospital, Chinese Academy of…
NCT07034742 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Gastric cancer is one of the most prevalent and lethal malignancies in China. The majority of patients are diagnosed at the locally advanced stage. Despite standard treatment involving radical resection combined with adjuvant chemotherapy, approximately 40% of patients experience recurrence and metastasis, with peritoneal metastasis accounting for nearly half of these cases. Building upon our team's previous establishment of next-generation sequencing (NGS) technology for detecting molecular residual disease (MRD) in peritoneal lavage fluid and blood, this project aims to guide systemic chemotherapy with or without intraperitoneal chemotherapy for locally advanced gastric cancer patients based on the results of peritoneal lavage fluid MRD testing. We will investigate whether intraperitoneal chemotherapy can reduce the peritoneal metastasis rate in patients testing positive for MRD in pe

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically confirmed adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma of the stomach or gastroesophageal junction (GEJ). * Clinical stage cT4NanyM0, deemed suitable for radical resection. * Age between 18 and 75 years. * ECOG performance status of 0 or 1. * No prior neoadjuvant therapy and strong patient/family preference for primary surgery. * Adequate organ function defined as: Absolute neutrophil count (ANC) \> 1.5 x 10⁹/L (or \> 1500/µL)；Hemoglobin (Hb) \> 90 g/L；Platelet count (PLT) \> 100 x 10⁹/L (or \> 100,000/µL)；Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \< 2.5 x Upper Limit of Normal (ULN)；Total bilirubin (TBIL) \< 1.5 x ULN；Serum creatinine (Cr) \< 1.0 x ULN * Good compliance and willingness to undergo long-term follow-up. * Provision of signed written informed consent. Exclusion Criteria: * Pathological specimens containing \>10% of other histological components (e.g., squamous cell carcinoma, neuroendocrine carcinoma, etc.). * Uncontrolled gastrointestinal obstruction or recurrent bleeding. * Inability to swallow oral medications. * Active infection requiring systemic therapy. * Moderate to severe cirrhosis due to any cause. * Cardiac function classified as NYHA class \> I. * History of myocardial infarction, unstable angina, stroke, or uncontrolled arrhythmia. * Anticipated inability to tolerate postoperative adjuvant chemotherapy. * Concurrent medical conditions that contraindicate chemotherapy. * Pregnancy or lactation; history of psychiatric illness; poor compliance.
💊

What it tests

  • Intraperitoneal chemotherapy PLUS systemic chemotherapy
📍

Where

1 site
Chaoyang District, Panjiayuan Nanli NO.17
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy